UN authorises second malaria vaccine; experts warn it's not enough to stop the disease spreading

In 2021, WHO endorsed the first malaria vaccine in what it described as a historic effort to end the devastating toll the mosquito-transmitted disease has on Africa, home to most of the world's estimated 200 million cases and 400,000 deaths. But that vaccine, known as Mosquirix and made by GSK, is only about 30% effective, requires four doses and protection fades within months.

London:The World Health Organisation authorised a second malaria vaccine on Monday, a decision that could offer countries a cheaper and more effective option than the world's first shot against the parasitic disease. WHO Director-General Tedros Adhanom Ghebreyesus said the UN health agency was approving the new malaria vaccine based on the advice of two expert groups, recommending its use in children at risk of the disease.

As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two, Tedros said. Oxford University developed the new three-dose vaccine with help from the Serum Institute of India. Research suggests it is more than 75% effective and that protection is maintained for at least another year with a booster. Tedros said the shot would cost about $2 to $4 and could be available in some countries next year.

Earlier this year, regulatory authorities in Ghana and Burkina Faso approved the vaccine. This is one more tool we will now have, but it's not going to replace bed nets and spraying insecticides, said John Johnson with Doctors Without Borders. This is not the vaccine that's going to stop malaria. Johnson was not part of the WHO expert group that gave the Oxford vaccine the green light.

In 2021, WHO endorsed the first malaria vaccine in what it described as a historic effort to end the devastating toll the mosquito-transmitted disease has on Africa, home to most of the world's estimated 200 million cases and 400,000 deaths. But that vaccine, known as Mosquirix and made by GSK, is only about 30% effective, requires four doses and protection fades within months.

The Bill & Melinda Gates Foundation, one of the vaccine's biggest backers, stepped back last year from financially supporting Mosquirix's rollout, saying it was less effective than officials would like and that funding would be better used elsewhere. The big difference with these two vaccines is access, Johnson said, noting that only about a dozen countries are scheduled to get limited quantities of the GSK vaccine in the next few years.

GSK has said it can only produce about 15 million doses a year. The Serum Institute has said it could make up to 200 million doses of the Oxford vaccine a year.

Alister Craig, an emeritus professor at the Liverpool School of Tropical Medicine, said he would recommend countries trying to get the GSK vaccine switch to the Oxford vaccine instead. Craig noted that no big funders have yet agreed to buy the Oxford vaccine for poor countries and it's still unclear how effective the shot might be in the long term.

If the new vaccine is rolled out widely across Africa, it could dramatically reduce the amount of severe illness and deaths caused by malaria in a few years, Craig said. Neither of the malaria vaccines stop transmission so immunization campaigns alone won't be enough to stop epidemics. Efforts to curb the disease are also being complicated by increasing reports of resistance to the main drugs used to treat malaria and the spread of invasive mosquito species.

You would be foolish to think that this vaccine is going to be the end of the malaria story," Craig said. In a separate decision, WHO's expert group also authorised the dengue vaccine made by Takeda, which was previously approved by the European Union drug regulator. There is no specific treatment for dengue, common in tropical Latin American and Asian countries. While most infections are mild, severe cases of the mosquito-spread disease can lead to internal bleeding, organ damage and death.

WHO's expert groups advised that the Takeda dengue vaccine be used in children aged 6 to 16 in countries with a high prevalence of the disease. Previous studies have showed Takeda's vaccine was about 84% effective in preventing people from being hospitalised with dengue and about 61% effective in stopping symptoms four years after getting immunised. Nearly 1,000 people have been killed by dengue this year in an ongoing epidemic in Bangladesh, the country's worst outbreak of the disease. (AP)